Content area
Full Text
Risk-stratified tapering of disease-modifying antirheumatic drug (DMARD) dosage using an algorithm appears to be feasible in patients with rheumatoid arthritis (RA) and reduces costs, according to findings of an analysis of the German RETRO study presented as an abstract at the 18th Annual Congress of the European League Against Rheumatism (EULAR) in June 2017.1
The feasibility and direct treatment costs of risk-stratified DMARD tapering, using an algorithm based on Multiple-Biomarker Disease Activity (MBDA) score and anti-citrullinated protein antibody (ACPA) status, were evaluated in 146 patients with RA in sustained remission. During the one-year study period, patients...